Effect of Raloxifen on Renal Function in Post-Menopausal Women with Diabetic Nephropathy: a Double Blind Clinical Trial
- *Corresponding Author:
- Zahra Shajari
Vali-e-asr Hospital, Zanjan Metabolic Diseases Research Center
Zanjan University of Medical Sciences, Zanjan, Iran
Tel: 0098 2417270814
Fax: 0098 2417270815
E-mail: [email protected]
Received Date: June 02, 2013; Accepted Date: August 19, 2013; Published Date: August 21, 2013
Citation: Sharifi F, Shajari Z, Rahimi M, Mousavinasab N (2013) Effect of Raloxifen on Renal Function in Post-Menopausal Women with Diabetic Nephropathy: a Double Blind Clinical Trial. J Nephrol Ther 3:135. doi:10.4172/2161-0959.1000135
Copyright: © 2013 Sharifi F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: This study evaluates the effects of the selective estrogen receptor modulators (SERMs), raloxifen, on renal function in post- menopausal women with type 2 diabetes mellitus.
Methods: Thirty-seven post-menopausal women with Type 2 diabetes and diabetic nephropathy included in a 4-month, double-blind, placebo-controlled trial. 18 patients received 60 mg raloxifene per day and 19 patients received placebo. Baseline and end-study body mass index (BMI), blood pressure (BP), fasting plasma glucose (FPG), HbA1C, lipid profiles and serum creatinine (Cr) were measured. Albumin/creatinin ratio (ACR) and GFR were calculated for all the participants.
Results: Mean ACR log was decreased significantly in the raloxifene group (2.4 ± 0.63 μg/mg vs. 1.89 ± 0.8 μg/ mg; P=0.009), but slight-non-significant changes in the placebo group were seen (2.16 ± 0.53 vs. 2.12 ± 0.83; P=0.8). In addition, compared with placebo, raloxifene resulted in no significant changes in GFR, HbA1C, lipid profiles and BMI. After considering variables like age, sex, duration of diabetes, duration of menopause, BMI, systolic blood pressure (SBP) and diastolic blood pressure (DBP) as confounding factors the improving effect of raloxifene on ACR remained significant.
Conclusion: These results suggest that raloxifene may limit the progression of albuminuria in post-menopausal women with diabetes; further studies in a larger population may be warranted.